Lymphoma
Concurrent chemoradiotherapy used to treat nasal NK/T cell lymphoma
Published in Cancer Weekly, February 21st, 2006
"NK/T cell lymphoma is a rare subtype of lymphomas, being a subtype of non-Hodgkin lymphoma with a much worse prognosis than other subtypes. One reason for this worse prognosis is that nasal NK/T cell lymphoma is resistant to standard sequential chemoradiotherapy," researchers in Japan reported.
"Thus, we adopted concurrent chemoradiotherapy using a CHOP-like regimen for treating stage I nasal NK/T cell lymphoma. Case 1 was treated with concurrent chemoradiotherapy using 41-Gy irradiation with 12 cycles of the CHOP-like regimen (THP-CVP). Case 2 was...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2006-02-21)
More Articles from Cancer Weekly
- Brain Cancer
TWIST is expressed in human gliomas and promotes invasion - Cancer Drugs
Doxorubicin-induced cardiotoxicity could be prevented by melatonin - Colorectal Metastases
Recent chemotherapy reduced sensitivity of FDG-PET in detecting colorectal metastases - Lung Cancer
JNK activation required for gemcitabine's cytotoxic effect in lung cancer - Pituitary Tumors
Mimecan gene expression used as a marker for diagnosing pituitary tumors - Acute Myeloid Leukemia
Modified conventional protocol for childhood AML well tolerated - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
